Related Experiment Videos
Antithrombotic and thrombolytic therapy in patients undergoing coronary artery interventions: a review
1Toronto General Hospital, Ontario, Canada.
Insights
Coronary interventions cause arterial injury, increasing thrombotic occlusion risk. While aspirin and heparin help acutely, only the antiplatelet agent 7E3 effectively reduces restenosis after angioplasty.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Thrombosis Research
Background:
- Coronary interventions like balloon angioplasty cause arterial injury, leading to platelet activation and risk of thrombotic occlusion.
- Factors such as unstable presentation, complex lesions, and dissection heighten this thrombotic risk.
- Acute complications are reduced by aspirin and heparin, standard periprocedural treatments.
Purpose of the Study:
- To evaluate the effectiveness of antiplatelet and anticoagulant agents in managing complications of coronary interventions.
- To investigate the role of these agents in preventing restenosis post-angioplasty.
- To explore potential new therapeutic strategies for long-term patient management.
Main Methods:
- Review of existing literature on periprocedural and long-term management of coronary interventions.
- Analysis of the efficacy of aspirin, heparin, thrombolysis, and specific antiplatelet agents like 7E3.
- Assessment of factors influencing thrombotic risk and restenosis rates.
Main Results:
- Aspirin and heparin are effective in reducing acute complications but not restenosis.
- Thrombolysis is rarely needed acutely but may be useful for saphenous vein graft lesions with thromboembolization.
- The antiplatelet agent 7E3, targeting the IIb/IIIa receptor, decreased the 6-month clinical event rate after balloon angioplasty.
Conclusions:
- Current anticoagulants and most antiplatelet agents are ineffective in preventing restenosis after coronary interventions.
- The antiplatelet agent 7E3 shows promise in reducing clinical events, possibly via surface pacification.
- Newer, potent antiplatelet and anticoagulant agents may play a role in the long-term management of patients undergoing coronary interventions.
Abstract:
The controlled arterial injury that occurs with balloon angioplasty and other coronary interventions is characterized by evanescent endothelial denudation and vascular disruption. As a consequence, platelet activation occurs at the treated site, and there is a risk of thrombotic occlusion. This risk is heightened by several factors including unstable clinical presentation, lesion complexity, deep injury, and dissection. Aspirin has been shown to unquestionably reduce, although not eliminate, acute complications and is now part of the routine periprocedural regimen. Heparinization with more intense anticoagulation than is conventionally used is also standard treatment and is initiated before vessel instrumentation. Adjunctive thrombolysis is rarely necessary unless refractory thrombus precedes or complicates the procedure. However, thrombolysis may have a role in the treatment of saphenous vein graft obstructive lesions in which guide wire- or catheter-induced distal thromboembolization may cause infarction in spite of successful graft recanalization. In contrast to their success in the periprocedural phase of coronary interventions, anticoagulants and a wide variety of platelet active agents have been ineffective in reducing the 30% to 40% incidence of restenosis. Only 7E3, which targets the final common pathway of platelet aggregation by irreversibly blocking the IIb/IIIa receptor, has been shown to decrease the 6-month clinical event rate after balloon angioplasty, possibly by a surface pacification mechanism. This suggests that newer more potent antiplatelet and anticoagulant agents may also find a role in the long-term management of these patients.